SMMT Q3 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$220,000-83.2% YoY

Gross Profit

$220,000100.0% margin

Operating Income

-$17M-7700.0% margin

Net Income

-$21M-9720.5% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-6.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$155M

Total Liabilities

$22M

Stockholders' Equity

$133M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220,000	$1M	-83.2%
Gross Profit	$220,000	$1M	-83.2%
Operating Income	-$17M	-$19M	+13.1%
Net Income	-$21M	-$20M	-9.1%

Revenue Segments

License and Service

$220,000100%

Geographic Segments

Latin America

$220,000100%